Sponsor
Nanette Barragán
Representative · D-CA
Representative · D-CA
This bill speeds patient access to certain competing drugs and may lower prices, but does so by allowing omission of some labeling content—creating safety, legal, and incentive risks and increasing FDA oversight burdens.
Patients with unmet needs and hospitals/health systems get faster access to certain generic and 505(b)(2) drugs even when some exclusivity-protected labeling language is omitted, expanding immediate treatment options.
Competitors can enter the market despite exclusivity-limited labeling, which can increase supply and downward pressure on drug prices for patients and taxpayers over time.
Patients (especially those with chronic conditions) may receive drugs with labeling that omits certain safety details, increasing the risk of under-informed use and adverse outcomes.
Holders of exclusivity or patent owners could see weakened protection for labeling-based exclusivity, reducing incentives for costly drug development and potentially slowing future innovation.
The FDA will need to expend additional regulatory resources to craft compensatory safety statements and perform oversight, which could divert staff/time from other review activities.
Based on analysis of 2 sections of legislative text.
Prevents FDA from denying approval or treating as misbranded a 505(b)(2) or 505(j) drug solely because labeling omits safety info protected by exclusivity or patent, while allowing FDA to require necessary safety statements.
Allows the FDA to approve generic or 505(b)(2) drugs even when their proposed labeling omits certain safety information that is still protected by exclusivity or patents, so long as the omission is solely due to that protected status. The FDA must still require any safety statements it finds necessary to ensure safe use. The change narrows one ground for denying approval or treating a product as misbranded, while preserving other exclusivity and patent rights.
Official title: To amend the Federal Food, Drug, and Cosmetic Act to provide for the prompt approval of drugs when safety information is added to labeling, and for other purposes.
Introduced January 31, 2025 by Nanette Barragán · Last progress January 31, 2025